La Jolla Pharmaceutical Co. (NASDAQ:LJPC)’s share price fell 3.8% during trading on Wednesday . The company traded as low as $16.42 and last traded at $16.56, with a volume of 56,680 shares traded. The stock had previously closed at $17.21.

A number of brokerages have commented on LJPC. Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, August 25th. Lake Street Capital began coverage on shares of La Jolla Pharmaceutical in a research note on Tuesday, May 24th. They set a “buy” rating and a $25.00 target price on the stock. Jefferies Group reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 8th. Finally, SunTrust Banks Inc. began coverage on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 22nd. They set a “buy” rating and a $30.00 target price on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $38.83.

The firm’s 50 day moving average price is $17.40 and its 200 day moving average price is $17.83. The company’s market capitalization is $298.45 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.99) by $0.09. On average, equities analysts anticipate that La Jolla Pharmaceutical Co. will post ($3.76) EPS for the current year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.